A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy

NCT04229615 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

690

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Carcinoma

Interventions

DRUG: Fluzoparib; Apatinib
DRUG: Fluzoparib
DRUG: Placebo

Sponsor

Jiangsu HengRui Medicine Co., Ltd.